Bio.Me Femme V 60 Capsule

A multi-species probiotic with specific strains that have undergone in-vivo, ex-vivo and in-vitro testing for their efficacy, mode of action and safety.

Bio.Me Femme V is the only available vaginal probiotic containing Lactobacillus crispatus on the market. This multi-species formula contains keystone Lactobacilli for optimal lactic acid production, pH and pathobiont inhibition.

The probiotic has undergone human clinical trials which have shown colonisation in the vagina after oral ingestion, as well as a significantly reduced reoccurrence of bacterial vaginosis after antibiotic treatment.

Available in 30s and 60s

Dairy free, gluten free, vegan, non GMO

Directions


Take 1 capsule per day.  Do not exceed the recommended dose, unless advised by your healthcare professional.

Or
1 capsule inserted vaginally for 7 days after menstrual cycle, repeated as necessary.

Ingredients

Download tech sheet

References

 

1. Mezzasalma V, Manfrini E, Ferri E, Boccarusso M, Di Gennaro P, Schiano I, et al. Orally administered multispecies probiotic formulations to prevent uro-genital infections: a randomized placebo-controlled pilot study. Arch Gynecol Obstet. 2017;295(1):163–72.

 

2. Mezzasalma V, Manfrini E, Ferri E, Sandionigi A, La Ferla B, Schiano I, et al. A Randomized, Double-Blind, Placebo-Controlled Trial: The Efficacy of Multispecies Probiotic Supplementation in Alleviating Symptoms of Irritable Bowel Syndrome Associated with Constipation. Biomed Res Int [Internet]. 2016 [cited 2019 Sep 20];2016:4740907. Available from: http://www.ncbi.nlm.nih.gov/ pubmed/27595104

 

3. Presti I, D’Orazio G, Labra M, La Ferla B, Mezzasalma V, Bizzaro G, et al. Evaluation of the probiotic properties of new Lactobacillus and Bifidobacterium strains and their in vitro effect. Appl Microbiol Biotechnol. 2015;99(13):5613–26.

 

4. Petrova MI, Lievens E, Malik S, Imholz N, Lebeer S. Lactobacillus species as biomarkers and agents that can promote various aspects of vaginal health. Front Physiol. 2015;6(MAR):1–18.

 

5. Atassi F, Brassart D, Grob P, Graf F, Servin AL. Lactobacillus strains isolated from the vaginal microbiota of healthy women inhibit Prevotella bivia and Gardnerella vaginalis in coculture and cell culture. FEMS Immunol Med Microbiol [Internet]. 2006 Dec 1 [cited 2019 Apr 17];48(3):424–32. Available from: https://academic.oup.com/femspd/article-lookup/doi/10.1111/j.1574- 695X.2006.00162.x

 

6. Van Der Veer C, Hertzberger RY, Bruisten SM, Tytgat HLP, Swanenburg J, De Kat Angelino-Bart A, et al. Comparative genomics of human Lactobacillus crispatus isolates reveals genes for glycosylation and glycogen degradation: Implications for in vivo dominance of the vaginal microbiota. Microbiome. 2019;7(1):1–14.

 

7. Verstraelen H, Verhelst R, Claeys G, De Backer E, Temmerman M, Vaneechoutte M. Longitudinal analysis of the vaginal microflora in pregnancy suggests that L. crispatus promotes the stability of the normal vaginal microflora and that L. gasseri and/ or L. iners are more conducive to the occurrence of abnormal vaginal microflora. BioMed Cent Microbiol [Internet]. 2009 [cited 2019 Aug 8];9(116). Available from: http://www.biomedcentral.com/1471-2180/9/116

 

8. Murina F, Vicariotto F. Evaluation of an Orally Administered Multistrain Probiotic Supplement in Reducing Recurrences Rate of Bacterial Vaginosis: A Clinical and Microbiological Study. Adv Infect Dis. 2019;09(03):151–61.

 

INO031